期刊文献+

左旋多巴甲酯缓释微球的研究 被引量:2

Research of Levodopa Methyl Ester-loaded Microspheres Delivery System
原文传递
导出
摘要 目的:由于长期服用左旋多巴治疗帕金森病,其药物浓度波动刺激易引起异动症,本实验旨在制备突释小,药物释放浓度稳定的左旋多巴甲酯微球制剂。方法:将左旋多巴甲酯用复乳法包裹于PLGA微球内,采用C18反相色谱研究药物包封率和体外释放行为。结果:通过调节药物浓度和不同高分子组合筛选出突释小,包封率高且缓慢释放的处方。结论:左旋多巴甲酯包裹于PLGA能实现理想的缓释效果,降低药物浓度波动,为后期药效学实验提供基础。 Objective: Chronic administration of levodopa in the treatment of PD leads to debilitated involuntary movements, we aimed to prepare levodopa methyl ester-loaded sustained release microspheres without initial burst. Methods: Levodopa methyl ester (LDME) were microencapsulated into PLGA microspheres by multiple emulsion technique. The encapsulation efficiency and vitro release of microspheres were detected using HPLC system equipped with a C18 reverse column. Results: By adjusting LDME concentration and different polymer combinations, we achieved microspheres with high encapsulation efficiency, low initial burst and sustained release. Conclusions: LDME would achieve sustained release while encapsulated into PLGA microspheres, which provided a basis for later pharmacodynamic study.
机构地区 上海交通大学
出处 《现代生物医学进展》 CAS 2011年第11期2034-2036,共3页 Progress in Modern Biomedicine
基金 国家重大专项-"重大新药创制"科技重大专项-创新药物研究开发技术平台(2009ZX09310-007) 上海科委项目(No.0952nm03700和No.1052nm03900) 上海交通大学大学生创新项目(IPP2090)
关键词 左旋多巴甲酯 PLGA微球 缓释 帕金森氏病 异动症 LDME PLGA microspheres Sustained release Parkinson's disease Levodopa-induced dyskinesia
  • 相关文献

参考文献17

  • 1Sherer TB, Betarbet R, Greenamyre JT. Pathogenesis of Parkinson's disease[J]. Curt Opin Investig Drugs, 2001,2(5):657-662.
  • 2周青,张世忠,徐如祥.帕金森病的治疗现状和展望[J].中国临床康复,2004,8(16):3102-3103. 被引量:3
  • 3Andres M, Iozano, Suneil K, Kalia. New Movement in Pakinson's [J]. Science, 2005,6:58-65.
  • 4Eskow KL, Dupre KB, Barnum CJ, et al. The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-in- duced dyskinesia in hemiparkinsonian rats [J]. Synapse, 2009, 63(7): 610-620.
  • 5Aubert I, Guigoni C, Li Q, et al. Enhanced preproenkephalin-B-de- rived opioid transmission in striatum and subthalamic nucleus con- verges upon globus pallidus intemalis in L-3,4-dihydroxypheny!ala- nine-induced dyskinesia[J]. Biol Psychiatry, 2007, 61(7):836-844.
  • 6Bishop C, Taylor JL, Kuhn DM, et al. MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HTIA receptor stimulation[J]. Eur J Neurosci, 2006, 23(10):2669-2676.
  • 7Jaunarajs KL, Dupre KB, Steiniger A, et al. Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia [J]. Neu- roreport, 2009, 20(14): 1265-1269.
  • 8Carta M, Carlsson T, Kirik D, et al. Dopamine released from 5-HT ter- minals is the cause of L-DOPA-indueed dyskinesia in parkinsonian rats[J]. Brain, 2007,130(Pt 7): 1819-1833.
  • 9Meissner W, Ravenseroft P, Reese R, et al. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involun- tary movements in the 6-OHDA-lesioned rat in the presence of exces- sive extracellular striatal dopamine [J]. Neurobiol Dis, 2006, 22(3): 586-598.
  • 10Morissette M, Dridi M, Calon F, et al. Prevention of levodopa-in- duced dyskinesias by a selective NRIA/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of pre- proenkephalin[J]. Mov Disord, 2006, 21 (1):9-17.

二级参考文献22

  • 1Paola RD, Uitti RJ. Treatment implications in the early detection of Parkinson' s disease. Med Pro SEA 1997; 24(1 ): 8
  • 2Poewe WH, Caraceni T. Dopamine agonists in the treatment of Parkinson' s disease. Neurology 1995; 45(suppl 3): S5
  • 3Wolters EC, Tissingh G, Bergmans PL, et al. Dopamine agonists in Parkinson' s disease. Neurology 1995;45(suppl 3): S28
  • 4Jenner P. The rationale for the use of dopamine agonists in Parkinson' s disease.Neurology 1995; 45 ( suppl 3 ): S6
  • 5Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson' s disease. Neurology 1995; 45 (suppl 3): S13
  • 6Pezzoli G, Martignoni E, Pacchetti C, et al. A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson' s disease. Neurology 1995; 45 (suppl 3 ): S22
  • 7Tan AK. Current and emerging treatment in Parkinson' s disease. Ann Acad Med (singapore) 2001; 30(2): 128- 33
  • 8Ankovic J. Parkinson' s disease therapy: tailoring choices for early and late,young and old patients. Clin Neuropharmacol 2000; 23 (5): 252 - 61
  • 9Olanow CW, Watts RL, Koller WC. An alogorithm (decisiontree)for the managements of Parkinson' s disease (2001): treatments guideline. Neurology 2001; 56(11 suppl 5): S1 -S88
  • 10Jacques F, Kim JB, Jamal MT, et al. Oulecome of unilateral and bilateral pallidotomy for Parkinson's disease: patient assessment. Neurosugery 2000; 46(2): 344 - 52

共引文献2

同被引文献32

  • 1周青,张世忠,徐如祥.帕金森病的治疗现状和展望[J].中国临床康复,2004,8(16):3102-3103. 被引量:3
  • 2蒋伟哲.左旋多巴甲酯盐酸盐的合成及纯化方法[C].中华人民共和国,200610125071.X[P]2007-04-25.
  • 3Sherer TB, Betarbet R, Greenarnyre JT. Pathogenesis of Parkinson's Disease [J]. Curt Opin Investig Drugs, 2001, 2(5):657-662.
  • 4Andres M, lozano, Suneil K, Kalia. New Movement in Pakinson's [J]. Science, 2005,6:58-65.
  • 5Eskow KL, Dupre KB, Barnum CJ, et al. The role of the dorsal raphen- ueleus in the development, expression, and treatment of L-dopa-induce- d dyskinesia in hemiparkinsonian rats [J]. Synapse, 2009, 63(7):610-620.
  • 6Aubert I, Guigoni C, Li Q, et al. Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges up-on globus pallidus intemalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia[J]. Biol Psychiatry, 2007, 61 (7):836-844.
  • 7Bishop C, Taylor JL, Kuhn DM, et al. MDMA and fenfluramine re- duce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stim- ulation[J]. Eur J Neurosci, 2006, 23(10):2669-2676.
  • 8Jaunarajs KL, Dupre KB, Steiniger A, et al. Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia [J]. Neu- roreport, 2009, 20(14): 1265-1269.
  • 9Carta M, Carlsson T, Kirik D, et al. Dopamine released from 5-HT ter- minals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats [J]. Brain, 2007,130(Pt 7):1819-1833.
  • 10Meissner W, Ravenscroft P, Reese R, et ah Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involunta- ry movements in the 6-OHDA-lesioned rat in the presence of excessi- ve extracellular striatal dopamine [J]. Neurobiol Dis, 2006, 22(3):586- 598.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部